RT Book, Section
A1 Gruenberg, Katherine
A1 Guglielmo, B. Joseph
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193122193
T1 Telavancin, Dalbavancin, Oritavancin
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193122193
RD 2024/04/20
AB Telavancin  was  the  first  approved  lipoglycopeptide  for  the  treatment  of  skin  and  soft  tissue  infection  due  to  resistant  gram-positive  bacterial  pathogens.  It  is  indicated  as  an  alternative  to  vancomycin  in  skin  and  soft  tissue  infection  and  hospital-acquired  and  ventilator-associated  bacterial  pneumonia.  Telavancin  displays  concentration-dependent  bactericidal  killing  and  a  7.5-hour  half-life  and  post-antibiotic  effect  of  4–6  hours  allowing  for  once-daily  dosing.  Taste  disturbance,  nausea,  headache,  foamy  urine,  prolonged  QT,  and  reversible  kidney  injury  are  the  most  commonly  observed  adverse  events.  Telavancin  has  a  boxed  warning  highlighting  the  increased  mortality  in  patients  with  preexisting  kidney  dysfunction  (creatinine  clearance  50  mL/min  or  less).  Similar  to  daptomycin  and  linezolid,  telavancin  is  useful  in  the  treatment  of  resistant  bacterial  infection  as  an  alternative  for  patients  who  are  intolerant  of  vancomycin.  However,  the  increased  mortality  risk  in  certain  patients  suggests  it  should  serve  a  secondary  role  in  the  treatment  of  serious  gram-positive  infection.